Clinical Trial Update: Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of sequential immunochemotherapy in refractory metastatic colorectal cancer, starting with pembrolizumab plus a dendritic cell vaccine an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Microsatellite-stable Colorectal Cancer
• Mismatch Repair-proficient Colorectal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Dendritic cell vaccine
• KEYTRUDA (PEMBROLIZUMAB)
• Lonsurf (trifluridine/tipiracil)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma | Phase 2 | Status: RECRUITING